Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal raises 2025 profit guidance as Q3 net revenue rises 12% to $785 million

Positive Impact 4 of 5 guidance Written later

Amneal reported third-quarter 2025 net revenue of $785 million, up 12% from $702 million a year earlier, and GAAP net income attributable to the company of $2 million, or $0.01 per diluted share, compared with a loss in the prior-year quarter. The company raised its 2025 adjusted EBITDA, adjusted diluted EPS and operating cash flow guidance and left net revenue guidance unchanged, while a $31.4 million loss on refinancing weighed on quarterly results.

Key points

  • Net revenue was $785 million, up 12%; Specialty rose 8%, Affordable Medicines rose 8% and AvKARE rose 24%.
  • GAAP net income attributable to Amneal was $2 million ($0.01 per diluted share); adjusted diluted EPS was $0.17, up 6% from $0.16.
  • 2025 adjusted diluted EPS guidance was raised to $0.75-$0.80 from $0.70-$0.75, and adjusted EBITDA guidance to $675-$685 million from $665-$685 million.
  • The quarter included a $31.4 million loss on refinancing tied to the August 1, 2025 borrowing of $2.1 billion in term loans and $600 million of senior notes due 2032.

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECOct 30, 2025, 6:19 AM ET
Accession number0001723128-25-000059

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.